REG - e-Therapeutics plc - Total Voting Rights

E-TherapeuticsAnnouncement

31/01/2024 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240131:nRSe3797Ba&default-theme=true

RNS Number : 3797B  e-Therapeutics plc  31 January 2024

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Total Voting Rights

 

 

London, UK, 31 January 2024 - e-therapeutics plc (AIM: ETX), a company
integrating computational power and biological data to discover
life-transforming RNAi medicines, announces that in accordance with the
Financial Conduct Authority's Disclosure and Transparency Rules, the Company
has 584,335,487 ordinary shares of 0.1 pence each in issue, none of which are
held in treasury. Therefore, the total number of voting rights in the Company
is 584,335,487.

 

The above figure of 584,335,487 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company.

 

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi, CEO                                                                 Tel: +44 (0)20 4551 8888

 Timothy Bretherton, CFO                                                            www.etherapeutics.co.uk (http://www.etherapeutics.co.uk)

      SP Angel Corporate Finance LLP                                                Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker

 Matthew Johnson/Caroline Rowe/Harry Davies-Ball (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines. The Company's
technology uses computation to capture and model human biology, identify novel
targets, and develop RNAi medicines against those targets that can be rapidly
progressed to the clinic.

 

ETX's proprietary HepNet™ platform enables the generation and analysis of
biological network models, providing a novel and mechanistic approach to drug
discovery. This approach explicitly considers the true complexity of biology
to make more reliable predictions from large complex data sets and ETX's
proprietary hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource.  The Company generates,
prioritises, and tests millions of hypotheses in silico to identify better
therapeutic targets with higher confidence.

 

GalOmic™, ETX's proprietary RNAi platform, enables targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by HepNet™. The focus on hepatocytes
offers the opportunity to tackle a wide variety of diseases.  The liver is a
highly metabolically active organ which performs a key role in many biological
processes and vital functions crucial for human health. ETX's GalOmic™
constructs have demonstrated compelling in vivo performance in terms of depth
of gene silencing and duration of action.

 

The Company is progressing a pipeline of first-in-class RNAi candidates across
a variety of therapeutic areas with high unmet need, including preclinical
programs in cardiometabolic and metabolic diseases, haemophilia, and other
undisclosed indications. ETX has also partnered with biopharma companies such
as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational
network biology approach across a diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRZZGFMGGMGDZM